Ziege anti-Maus Immunoglobulin G2a (IgG2a) Antikörper (HRP)

Antigen: Immunoglobulin G2a (IgG2a)

Klonalität: Polyklonal

Wirt: Ziege

Reaktivität: Maus

Konjugat: HRP

Applikation: ELISA, Durchflusszytometrie (FACS), Immunfluoreszenz (IF)

Produktnummer: ABIN376250

Produktbeschreibung

Weitere Bezeichnung: IgG2a

Immunogen: Source: Pooled antisera from goats hyperimmunized with mouse IgG 2a paraproteins. Cross Absorption:Source: Pooled antisera from goats hyperimmunized with mouse IgG 2a paraproteins.

Isotyp: IgG

Spezifität: Reacts with the heavy chain of mouse IgG 2a as demonstrated by ELISA and flow cytometry. Minimal cross reactivity with human immunoglobulins.

Anwendungen

Applikationshinweise: ELISA: HRP conjugate:1:4,000-1:8,000 Other Applications: Since applications vary, you should determine the optimum working dilution of the product that is appropriate for your specific need. IMMUNOFLUORESCENT STAINING Amount Used: under 1µg/106 cells

Reinigung: Cross Absorption: Mouse IgM, IgG 1 , IgG 2b , IgG 3 and IgA, pooled human sera and purified human paraproteins. Purification:Affinity chromatography on mouse IgG 2a covalently linked to agarose.

Buffer: The purified (UNLB) antibody is supplied as 1.0 mg purified immunoglobulin in 1.0 mL of 100 mM borate buffered saline, pH 8.2. No preservatives or amine-containing buffer salts added. Store at 2-8°C. The fluorescein (FITC), rhodamine (TRITC), Texas Red Â

Lagerung: Store at 2-8°C

Forschungsgebiet: Sekundärantikörper

Beschränkungen: Nur für Forschungszwecke einsetzbar

Publikationen

Publikationen: Stegmann, Kamphuis, Meijerhof et al.: "Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation." in: Vaccine, 2010 (PubMed).

Yu, Vajdy: "A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations." in: Vaccine, 2011 (PubMed).

Staszewski, Reece, ODonnell et al.: "Drug treatment of malaria infections can reduce levels of protection transferred to offspring via maternal immunity." in: Proceedings. Biological sciences / The Royal Society, 2012 (PubMed).